Back to results
US 10,329,624 B2Granted
Grading of breast cancer
AssigneesBiotheranostics, Inc., The General Hospital Corporation
InventorsXiao-Jun Ma, Dennis C. Sgroi, Mark G. Erlander
Life of this patent
Estimating the term…
Abstract
Methods and compositions for the identification of breast cancer grade signatures are provided. The signature profiles are identified based upon multiple sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for identification of cells as being in one or more particular stages and/or grades of breast cancer.
Claims16
A method of treating breast cancer in a human subject, said method comprising
- assaying a sample from the human subject for gene expression levels of CENPA (centromere protein A (17 kD), chromosomal location 2p24-p21), RACGAP1 (Rac GTPase activating protein 1, chromosomal location 12p13.2-p13.1), RRM2 (ribonucleotide reductase M2 polypeptide, chromosomal location 2p25-p24), and NEK2 (NIMA (never in mitosis gene a)-related kinase, chromosomal location 1q32.2-q41);
- determining a measure of similarity between the gene expression levels of the human subject and reference gene expression levels for a reference population of cancer subjects;
- and
- either (a) treating the human subject with an antitumor agent, chemotherapy, or surgical removal of cancer tissue if the measure of similarity is above a threshold;
- or (b) conducting a cytological examination of cells from the human subject if the measure of similarity is above the threshold.
2 more elements
A method of treating breast cancer in a human subject, said method comprising
- assaying a sample from the human subject for gene expression levels of CENPA (centromere protein A (17 kD), chromosomal location 2p24-p21), RACGAP1 (Rac GTPase activating protein 1, chromosomal location 12p13.2-p13.1), RRM2 (ribonucleotide reductase M2 polypeptide, chromosomal location 2p25-p24), and NEK2 (NIMA (never in mitosis gene a)-related kinase, chromosomal location 1q32.2-q41);
- comparing the gene expression levels of the human subject to corresponding reference gene expression levels for a reference population of cancer subjects;
- and
- either (a) treating the human subject with chemotherapy if the gene expression levels of the human subject are higher than the corresponding reference gene expression levels, (b) conducting a cytological examination of cells from the human subject if the gene expression levels of the human subject are higher than the corresponding reference gene expression levels, or (c) administering a breast cancer treatment other than chemotherapy if the gene expression levels of the human subject are lower than the corresponding reference gene expression levels.
1 more element
Dependencies are inferred from the claim text.